tolazamide has been researched along with repaglinide in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barton, P; Luker, T; Wenlock, MC | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jannetto, PJ; Langman, LJ | 1 |
1 review(s) available for tolazamide and repaglinide
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
2 other study(ies) available for tolazamide and repaglinide
| Article | Year |
|---|---|
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.
Topics: Acids; Albumins; Drug Design; Humans; Hydrogen-Ion Concentration; Lipids; Molecular Structure; Pharmaceutical Preparations; Protein Binding | 2011 |
Analysis of Hypoglycemic Drugs by Liquid Chromatography-Tandem Mass Spectrometry.
Topics: Chlorpropamide; Chromatography, High Pressure Liquid; Chromatography, Liquid; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Nateglinide; Pioglitazone; Rosiglitazone; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Tolazamide; Tolbutamide | 2024 |